Tuesday, October 15, 2013

How does the ACA affect health care professionals?

It's no secret that some government officials don't exactly agree with the new Affordable Care Act. All political views aside, how will this new law impact actual health care professionals, particularly Nurse Practitioners? And what is their role in the health care reform?

This infographic provides a snapshot of what has happened in the years since the Affordable Care Act was conceptualized and enacted, in addition to showing how nurse practitioners are contributing to primary care. 






Friday, October 11, 2013

Download the Brochure for IIR's Medicare Congress

Inquiries about IIR’s Medicare Congress 2014 event have been pouring in daily, so we are pleased to announce – the website and registration are now live!

You’ll see that we’ve expanded the program for 2014, and are excited to introduce the only event allowing you and your team to be "one and done” at the Medicare Congress, providing you with everything you need to excel in the upcoming year.

One of the ways that we’ve created your all-in-one event experience is by joining the Medicare Congress with IIR's D.U.A.L.S. Forum, providing Medicare and Medicaid executives an exclusive opportunity to network and learn from one another, creating the ultimate peer learning experience to maximize opportunities to serve this lucrative and complex population.

Additionally, the Medicare Congress has expanded to include:

• The re-energized Stars University
• An increased focus on networking with ACOs
• A full track dedicated to Increasing Membership & Creating the Ideal Customer Experience
• Another track devoted to Medical Management and Care Coordination for Medicare and Dually Eligible Members

The broader perspective at the Medicare Congress 2014 ensures your entire team will find something relevant and excel in your quest to provide higher quality, cost-efficient care to current and potential members. Your learning and networking experience will be the most productive one yet!

Want to learn more? Download our agenda!

Use code XP1907BLOG to register for the conference that helps drive next generation Healthcare through improved Clinical Care Management & Customer Centricity. If you have any questions about the agenda or event, feel free to email Kate Devery at kdevery@iirusa.com or visit the homepage.

We hope to see you, February 10-12 in New Orleans!

Cheers,
The Medicare Congress Team

The Medicare Congress Homepage
The Medicare Congress Twitter
The Medicare Congress LinkedIn




Monday, October 7, 2013

A Message from MDRP Sponsor IMS Health

As always it was wonderful to see many of you at the 18th Annual Medicaid Drug Rebate Program Summit! For those of you who did not attend, we hope to see you soon. To download the presentations from MDRP, please click here.

This year's conference was relevant and interesting thanks to all of the great speakers at the event. As we reflect back on the various topics covered at the conference and synthesize the information presented, we want to highlight for you the key themes, future trends, and takeaways that we observed. Hopefully you will find this helpful as you discuss enhancements to the GP compliance program with upper management and other key stakeholders in your organization.

Future Impacts on the GP Compliance Program
A lot of this year's themes seemed to entail future or forward thinking.

• Health Insurance Exchanges (HIX): HIXs are set to take effect in 2014 and most of the contracting has already been set with October as the sign up date. While contracting has not seen any dramatic changes (parallels other managed care contracts), some MCOs have aggressively sought the manufacturer Best Price. While this area will continue to evolve, we are awaiting more information on whether these plans will receive an exemption status and whether these plans will attempt the ever elusive risk sharing contracts. Key areas to watch out for are the bundling of the arrangements between the plans (e.g., Gold, Silver, Bronze) or potentially between your other commercial contracts with the same MCO. (See attached presentation)

• Gross to Net (Evolution of the GP Function): Many of you in the GP arena are beginning to take on broader roles in the area of Gross-to-Net. With Medicaid expansion and the expected growth of the 340B program, incorporating GP into the strategic decision making process is becoming increasingly more important. Additionally, making sure we reduce revenue leakage in those GTN reductions can not only increase our profile within our respective companies, but increase the bottom line. (See attached presentation)

• Bundling: While ACA was business as usual for some companies with respect to unbundling, it was a major change for others. Looking to the future, we seen some potential problems as government agencies cannot seem to agree on a definition. Diverging definitions of bundling between the OIG and CMS can have dire future consequences as we try and comply with both. We must continue to monitor these various definitions and work with counsel to manage our risk.

• Final Rule Readiness: We are currently blessed with regulatory purgatory. Which means that now is the time to get our documentation in order (e.g., Product Master - Get the information that will be relevant to the final rule). You will never look back on this time period again unless something goes wrong, and then it's too late.

• Systems: From a systems perspective, work flow improvement for claims processing is a must as managed Medicaid continues to grow and Medicaid expands. Companies should look to use multi-quarter trending on key thresholds to determine when to adjust/improve automated validations

Recent Developments / Updates
As we might expect, there are still many interesting current topics.

• Authorized Generics: ACA altered the definition of a wholesaler thereby permitting the sales to the secondary manufacturer of the authorized generic to be included. In order to include these sales, we need to first identify whether an AG exists (more complicated than at first blush) and how to incorporate the sales (evaluating the methodological tradeoffs). (See attached presentation)

• 340B: Many manufacturers are receiving checks from what we thought were covered entities. When evaluating these checks and how/whether to incorporate them into our calculations, we must first understand the reason for the refund (e.g., Program Violations vs. Program Eligibility).

• Medicaid Rebates: The volume of Medicaid rebates paid for Managed Medicaid utilization will continue to increase as more and more states shift their Medicaid drug risk to their Managed Medicaid providers. Due to this shift, it is even more critical that manufacturers scrutinize their Medicaid invoices as uncertainty surrounds the validation of the Managed Medicaid claims. An anonymous state survey conducted this past month indicated that over 75% of the state respondents are uncertain if the Managed Medicaid providers are performing ANY claim validations before they are submitted to the state. (Contact Lynn Lewis for further details)

• Current Enforcement: During the enforcement discussion, the US Attorney discussed a settlement with Amgen for $24.9 million on allegations that that Amgen made available and paid to long-term care pharmacy providers (e.g., Omnicare, Inc., PharMerica Corporation, and Kindred Healthcare Inc.) market-share and volume-based rebates, as well as grants, honoraria, speaker fees, consulting services, dinners, travel and purchase of unnecessary data, all related to Aranesp, and that these payments amounted to "kickbacks" under the False Claims Act. The government also asserted that Amgen's therapeutic interchange programs improperly encouraged the "switching" of patients using competitor drugs to Aranesp. The matter was settled to compromise disputed claims and with the express acknowledgement that Amgen was not admitting liability and the government was not admitting that its claims were not well-founded. Based on the settlement, it is unclear whether this was considered a success by the DOJ or a failure, but based on the fact that many manufacturers use market-share rebates/discounts in their typical contracting, it may be prudent to review these agreements in light of the settlement.

Please do not hesitate to contact any of us at IMS Health should you have any questions or like to discuss these or any other topics further.

Kind Regards,

David S. Chan Senior Principal, Managed Markets Services IMS Health ®
│ 310.350.7175 │dchan@us.imshealth.com




Tuesday, September 24, 2013

Missourians Advised To Resist Health Care Law

Over the past few months the government has been spending millions on advertising to create awareness for the upcoming Health Insurance Marketplace, which opens for enrollment on October 1st. The new marketplace will help millions of Americans customize a healthcare plan that best suits their needs. Although open enrollment is less than a week away, some state officials continue to discourage residents in participating.

Lt. Gov. Peter Kinder has a message for the thousands of Missourians looking for health insurance: Don't get it through an online marketplace that launches next week. "I would hope there would be active resistance to this law — that people would not sign up," Kinder said Monday. 

Later today President Obama and Bill Clinton will meet to discuss the value of the new exchange. With open enrollment just days away, how many people do you think will purchase their plan through an online marketplace?

Want to learn more about the future of the marketplace? At IIR's HIX Reloaded, we'll help you shape your strategy for the ever evolving marketplace. To learn more, download our agenda.

As a reader of this blog you'll receive 15% off the standard rate when you use code XP1810BLOG to register. We hope to see you November 14-16 in Baltimore, MD!




Monday, September 23, 2013

Arkanasas Insurance Department unveils premiums

Arkansas Insurance Department has been evaluating premiums for quite some time, concluding they would vary by age, the size of the family, tobacco usage and geography. However, the premiums are actually lower than what was originally projected. The state will provide three separate plans - bronze, silver, and gold.

Arkansas Insurance Commissioner Jay Bradford announced premium rates for the 71 qualified health insurance plans that will be sold on the individual market in the new Health Insurance Marketplace. The qualified Health Plan issuers offering plans are Celtic Insurance Company d/b/a Arkansas Health and Wellness Solutions, Arkansas Blue Cross and Blue Shield, Blue Cross and Blue Shield Multi-State, and QCA Health Plans, Inc. d/b/a QualChoice Health Insurance of Arkansas.

The plans will be sold on the Health Insurance Marketplace beginning October 1st. Examples of the premium rates can be found here.

Want to learn more about the future of the marketplace? At IIR's HIX Reloaded, we'll help you shape your strategy for the ever evolving marketplace. To learn more, download our agenda.

As a reader of this blog you'll receive 15% off the standard rate when you use code XP1810BLOG to register. We hope to see you November 14-16 in Baltimore, MD!




Friday, September 20, 2013

MDRP 2013 Day 3: Current criminal and civil Enforcement Activities to improve Corporate Compliance

This week we'll be featuring MDRP 2013 event posts from our content partners, Huron Life Sciences. Today's author, Sam Woronoff, covers day 3 of MDRP 2013. 

Leading legal representatives from a law firm, a major manufacturer, and US Attorney’s office shared their insights and gave examples of recent lawsuits in connection with Government Pricing. GP department have definite role and responsibilities in the awareness of commercial activities and enforcing compliance policies to protect the company from unnecessary lawsuits. They pointed out some of the red flag items and key indicators that GP can look for as warning signs for potentially illegal activities.

Some of the key topics involving Anti-kickback being focused on today include: Market Share Rebates, Active Intervention Programs, and Transparency in Bundling /Volume Discounts. Also, some questionable contracting and sales activity examples such as retroactive discounts, and discounts disguised as sampling were shared. GP may not have a great visibility in the communications between the sales representatives and customers, but GP can review the contract structure to ensure that the discounts are legitimate and no side agreements are in place. Also, GP can look out for increased sampling activity of billable products which is a big red flag for the DA’s office.

The legal world relies on the “Collective Knowledge Doctrine” which means if one employee of the company is aware of an illegal activity, the company as a whole attributed to it. Be sure a firm corrective action plan is in place and enforced within the company because usually violation of internal policies precedes any illegal contracting practices.

For more detailed information and examples shared today, download the presentation from the IIR website.




Thursday, September 19, 2013

MDRP 2013 Keynote Presentation: OIG Work Updates

This week we'll be featuring MDRP 2013 event posts from our content partners, Huron Life Sciences. Today's author, Rajiv Mehrotra, recaps our day 3 Keynote Presentation on OIG Work Updates 

The last day at the 2013 MDRP Annual Summit saw Mr. David Tawes from the OIG present on the “Recent OIG Work Involving Prescription Drug Pricing and Payments”. The presentation discussed the recent work and analyses that the OIG is performing especially around the Medicare Part B program.

As part of its recent work, the OIG looked at the current Medicaid Drug Rebates Program and evaluated how a similar program might work in a Medicare Part B setting with respect to rebate recoupments (unlike Medicaid, Medicare has no requirement for manufacturers to pay rebates for prescription drugs). To perform the analysis, the OIG included 60 drugs that accounted for 85% of Part B expenditures (approx. $13.9 billion) in 2011 and performed a rebate calculation similar to the Medicaid Drug Rebate Program using AMPs or ASPs for these drugs. The analysis showcased that such a program could potentially provide anywhere from 21-26% recoupments of the Part B expenditures for these drugs using a Medicaid Drug Rebate Program structure.

Though this recommendation was not entertained by the CMS at this time (CMS could not devote the necessary resources for a Part B rebate program evaluation ) it, nonetheless, doesn’t take away from the fact that this is something really big that was suggested by the OIG and this could be a huge deal for manufacturers. Manufacturers should definitely keep an eye out if something like this or a variant thereof picks back up in the future.

This is a must-have presentation for manufacturers. For more information, either grab a version from the MDRP website or visit the OIG website at for more details. See you all next year!




MDRP 2013 Track 4: Systems

This week we'll be featuring MDRP 2013 event posts from our content partners, Huron Life Sciences. Today's author, Rajiv Mehrotra, recaps our day 2 Track Session: Systems 

With the expectation of the AMP Final Rule being published in January 2014 (or even later this year according to some speakers), the life sciences industry is eagerly as well as apprehensively looking to all the changes it would bring to existing rules and regulations. The changes would inevitably need to be translated into amendments in methodology and operations as well as to the existing systems. With special regards to systems, manufacturers must start thinking today so that they are in a position to appropriately “Analyze”, “Prioritize”, and “Implement” the necessary systems in time and comply with the new requirements.

During the Systems Track at the 2013 MDRP Annual Summit, several speakers shared examples of some of the expected changes that may come with the AMP Final Rule and which would need to be included/updated within the respective systems. Some of the examples discussed potential base date AMP recalculations according to the new regulations while others suggested proactively thinking about bundling arrangements especially in light of any new definitions/understanding that may be provided by the CMS. Several vendors alluded to being able to provide software solutions that could help manufacturers with implementation of such changes and automation of solutions for the new requirements. 

In order for vendors to be able to provide successful solutions it, however, becomes extremely important for manufacturers to take a more involved approach in the implementation. To this end, many vendor presentations aimed at educating the manufacturers on the need to critically think about these implementations. One vendor discussed the importance of appropriately defining business rules and requirements upfront and how that could serve as the building blocks for a successful system implementation. Another vendor added that manufacturers must think about system implementation more holistically – this meant identifying current issues and shifts in focus (e.g. moving from a Fee-for-Service Medicaid model to a Managed Medicaid model), transferring processes to systems, performing validations and evaluating impact of these changes, among others.

To round up the presentations, one vendor discussed its view of systems implementation in 2020. According to the vendor, the systems implementation model should shift toward a transformational model, a concept that is based upon understanding the current as well as the future trends of the industry and the manufacturer while also paying special attention not just to systems needs but also people and process needs. This “Transformational Journey Roadmap” would allow manufacturers to build a much broader view of not only how their business needs are met by the systems but also how the systems fit into the overall company’s people and process environment. Promising better efficiency and flexibility, this new transformational model would allow manufacturers to effectively change and improve based upon a future state vision and roadmap.

The 2013 MDRP Conference was a great event. Tons of exciting presentations and lots of new information to absorb. Kudos to the organizers! If you haven’t already, do provide your evaluations of what you thought of the conference to the organizers.




Wednesday, September 18, 2013

MDRP 2013 Track 3: State

This week we'll be featuring MDRP 2013 event posts from our content partners, Huron Life Sciences. Today's author, Sam Woronoff, recaps day 2 Track Session: State

A Panel of manufacturers and state representatives shared their thoughts on the recent online surveys were sent to states regarding how the states are validating the MDRP rebate claims data. Based on 32 states’ responses, the survey suggested that in regards to FFS claims data, majority of the state had confidence in their claims data validation process. However, when it comes to the MCO claims data, majority of the states responded that either no validation process was in place or had serious deficiency. As for the 340B claims, some states are relying strictly on voluntary disclosure from contract pharmacies participating in stock replacement as an only source for excluding claims. With the growing trend of MCO claims in MDRP and serious lack in states’ ability to validate the MCO claims data, the manufacturers need to be aware of this gap and be proactive in their invoice validation efforts.

Kudos for the MDRP Collaborative Workgroup for their efforts to create and standardize the electronic formats for claims level details (CLDs) and ROSI/ PQAS! Their efforts will accommodate both the manufacturers and the states to improve invoice validation and dispute resolution efforts, as well as efficiency in processing quarterly invoices! It was great to see the collaborative efforts of the manufacturers and states. Thank you guys!

To this date, the workgroup has developed a standardized CLD format as well as improving the electronic data file for ROSI/ PQAS. The standardized CLD format will be using common language for CLD data to decrease data manipulation, improve operational efficiencies, resource management and compliance control. In addition, they have included 340B indicators into the CLD format. The improved electronic ROSI/PQAS data file was created to minimize both manufacturer and the states’ manual efforts and speed up the rebate process and reduce operating costs. The proposed data file will include the EFT payment information as well.

The workgroup now needs manufacturer’s participation and assistance in pushing this effort into the next level by reviewing and providing feedback for the CLD and ROSI/PQAS data file drafts and reaching out to CMS directly to enforce the importance of this effort for the benefit of the entire MDRP rebate stakeholders.

For more information or to review the proposed CLD format, contact:

Stefano Paoloni Stefano.paoloni@dhs.state.nj.us 
Lynn Lewis llesix@us.imshealth.com  

One pharmaceutical manufacturer has shared their experience in implementing the Texas reporting process and their effort in overcoming challenges. They shared their stance and their methodology for addressing the timing issue, price change definition, and the price point determinations. For detailed information, reach out to IIR for a copy of Michael Hepburn’s presentation deck.

A representative from a leading manufacturer shared their vast insights and experiences in Medicaid Supplemental Contracting. There are many details and nuances in each state’s supplemental bids to understand and to consider. She has shared detailed tips and examples useful for manufacturers to refer to when completing a bid.

Also, some great tips and tools for disputing questionable utilization in Medicaid rebate invoices were shared today. Be sure to know your product, communicate readily with states, and be proactive for the effective dispute resolution process. States are just as eager as manufacturers to reach resolution. The industry is moving forward in the positive direction to work together to become more efficient and knowledgeable as well as resourceful. This track provided great insights and practical knowledge applicable to manufacturers involved in the day to day operation of MDRP.




MDRP 2013 Track 2: Finance

This week we'll be featuring MDRP 2013 event posts from our content partners, Huron Life Sciences. Today's author, Dana Zelig, recaps our Track 2 Session: Finance 

As anticipated, attendance at MDRP 2013 was both impressive and diverse, with delegates from pharma manufacturers, external counsel, consultants and system providers, state Medicaid agencies, and Federal programs. To keep so many people interested and engaged, IIR organized Tuesday afternoon’s sessions to allow attendees to move seamlessly between tracks to catch presentations on their hot topics, or by their favorite presenters. This was evident in the Financial Implications to Government Pricing Programs track, where the dynamics of the room changed with each session.

David Chan and Ari Ilan from IMS Health provided their insights on the commercial process and how it impacts GP. Sometimes, especially at large organizations, people are put in a silo and have little visibility to processes outside of theirs. But as IMS outlined, Commercial and GP must go hand in hand to maximize profitability and reduce risk.

Jennifer Lospinoso of KPMG spoke about her experience assisting pharma clients with Accruing and Forecasting. Her insight extended not just to traditional accruals performed by Finance functions, but also to incorporating Medicaid payments, and preparing for the AMP Final Rule.

Jennifer Norton of Vertex Pharmaceuticals discussed the difference between Fee for Service and Managed Care Organization rebates, and how it can impact manufacturers. She emphasized the importance of looking at these rebates from all angles, because they are viewed differently by people in different parts of your organization. It’s an issue that could affect people at every level of your organization, so make sure you know what questions to ask.

Stephen Ruscus from Morgan Lewis presented on the Branded Prescription Drug Fee, and provided background on the genesis of the fee as well as steps for calculating it. He fielded questions from manufacturers with very real concerns about where to get the data they needed to perform the calculations.

Finally, Chris Cobourn of CIS wrapped up the track by giving the GP professionals in the room the steps they need to stand on their GP soapbox and take ownership of requirements impacting their organizations. He aptly noted that even though we are waiting for the AMP Final Rule, we are by no means sitting on our hands with nothing to do. We are busy now, and we’re going to get busier once the Final Rule comes out, so we might as well get our ducks in a row.